Rak
0000358654
Donate

Oncoindex 01-2019

To calculate the current Oncoindex value we analysed 88 medicines which are registered in Europe since 2004 and appear in the European Society for Medical Oncology (ESMO) guidelines. 44 of them (50%) are not reimbursed in Poland, 29 (33%) are reimbursed with restrictions which have no medical basis, while only 15 medicines (17%) are reimbursed in line with current medical knowledge.

-70
Change history

Oncoindex change history

SUBONCOINDICES FOR

Solid tumours and haemato-oncological diseases

Find out more about how we calculate a Suboncoindex.

Oncoindex for individual types of cancer

Therapeutic area (type of cancer) Index value Change in relation to 2018-11
Malignant bronchial and lung cancer -69 image/svg+xml -4.15%
Malignant colon cancer -75 image/svg+xml -5%
Malignant breast cancer -90 image/svg+xml -10%
Malignant stomach cancer -75 image/svg+xml 25%
Malignant pancreatic cancer -75 0%
Malignant prostate cancer -50 0%
Malignant bladder cancer -100 0%
Malignant rectal cancer -75 image/svg+xml 25%
Malignant ovarian cancer 0 0%
Multiple myeloma and plasma cell neoplasms -78 image/svg+xml -11.11%
Myeloid leukaemia -67 0%
Lymphocytic leukaemia -39 image/svg+xml 21.42%
Other and indeterminate non-Hodgkin’s lymphomas -50 0%
Diffuse non-Hodgkin’s lymphomas -75 0%
Hodgkin’s disease -50 0%
Follicular non-Hodgkin’s lymphoma -100 0%
Peripheral and cutaneous T-cell lymphoma -50 0%